Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL)

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Hanlon, Katy ^a,b   Rudin, Claudius E ^a   Harries, Lorna W ^a,b  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH AND IMMUNOGLOBULIN LIKE DOMAIN 1; MICRORNA; MICRORNA 15A; MICRORNA 16 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; PROTEIN BAZ2A; PROTEIN RNF41; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 5; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; RNA;

ARTICLE; CARCINOGENESIS; CHROMOSOME 13Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; BIOLOGY; BIOSYNTHESIS; CHROMOSOME; CHROMOSOME 13; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; IMMUNOPHENOTYPING; METABOLISM; METHODOLOGY; ULTRASTRUCTURE;

CHROMOSOMES; CHROMOSOMES, HUMAN, PAIR 13; COMPUTATIONAL BIOLOGY; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; RNA;

EID: 70349750269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007169     Document Type: Article

References (46)

1. Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia. N Engl J Med 333: 1052-1057.
2. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
3. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, et al. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97: 1566-1571.
4. La Starza R, Wlodarska I, Aventin A, Falzetti D, Crescenzi B, et al. (1998) Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 91: 231-237.
5. Schlade-Bartusiak K, Stembalska A, Ramsey D (2005) Significant involvement of chromosome 13q deletions in progression of larynx cancer, detected by comparative genomic hybridization. J Appl Genet 46: 407-413.
6. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, et al. (2001) Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 61: 6640-6648.
7. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, et al. (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95: 1925-1930.
8. Liu Y, Corcoran M, Rasool O, Ivanova G, Ibbotson R, et al. (1997) Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 15: 2463-2473.
9. Mabuchi H, Fujii H, Calin G, Alder H, Negrini M, et al. (2001) Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 61: 2870-2877.
10. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, et al. (2001) Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 97: 2098-2104.
11. Calin GA, Croce CM (2007) Investigation of microRNA alterations in leukemias and lymphomas. Methods Enzymol 427: 193-213.
12. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
13. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM (2006) MicroRNA expression and function in cancer. Trends Mol Med 12: 580-587.
14. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, et al. (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22: 1095-1105.
15. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA (2007) Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther 7: 1009-1019.
16. Doench JG, Sharp PA (2004) Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511.
17. Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126.
18. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
19. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
20. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
21. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
22. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102: 13944-13949.
23. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, et al. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109: 4944-4951.
24. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, et al. (2008) MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 105: 5166-5171.
25. Müller-Hermelink H, Montserrat E, Catovsky D, Harris N (2001) Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC. pp 127-130.
26. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, et al. (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8: 1640-1645.
27. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
28. AppliedBiosystems (2001) Relative quantitation of gene expression. User Bulletin #2: 11-15.
29. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
30. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial microRNA target predictions. Nat Genet 37: 495-500.
31. Jones MH, Hamana N, Nezu J, Shimane M (2000) A novel family of bromodomain genes. Genomics 63: 40-45.
32. Panagopoulos I, Strombeck B, Isaksson M, Heldrup J, Olofsson T, et al. (2006) Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol 133: 270-275.
33. Abdullah JM, Li X, Nachtman RG, Jurecic R (2001) FLRF, a novel evolutionarily conserved RING finger gene, is differentially expressed in mouse fetal and adult hematopoietic stem cells and progenitors. Blood Cells Mol Dis 27: 320-333.
34. Jing X, Infante J, Nachtman RG, Jurecic R (2008) E3 ligase FLRF (Rnf41) regulates differentiation of hematopoietic progenitors by governing steady-state levels of cytokine and retinoic acid receptors. Exp Hematol 36: 1110-1120.
35. Geli J, Kiss N, Lanner F, Foukakis T, Natalishvili N, et al. (2007) The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer 14: 125-134.
36. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ (2003) The proapoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 278: 21938-21943.
37. Aoyama Y, Avruch J, Zhang XF (2004) Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 23: 3426-3433.
38. Guil S, Esteller M (2009) DNA methylomes, histone codes and miRNAs: Tying it all together. Int J Biochem Cell Biol 41: 87-95.
39. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
40. Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner M, et al. (2004) Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 18: 1964-1970.
41. Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, et al. (2003) Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 70: 373-378.
42. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, et al. (2001) Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161.
43. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al. (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056.
44. Hedman H, Nilsson J, Guo D, Henriksson R (2002) Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354.
45. Hedman H, Henriksson R (2007) LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 43: 676-682.
46. Bentwich I (2005) Prediction and validation of microRNAs and their targets. FEBS Lett 579: 5904-5910.